A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Summary

The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.

Timeline

Start

2022-10-30

Primary completion

2025-06-16

Completion

2025-06-16

Drugs

Indications